[go: up one dir, main page]

MX2014001065A - Formulaciones de (trimetoxifenilamino) pirimidilino nuevas. - Google Patents

Formulaciones de (trimetoxifenilamino) pirimidilino nuevas.

Info

Publication number
MX2014001065A
MX2014001065A MX2014001065A MX2014001065A MX2014001065A MX 2014001065 A MX2014001065 A MX 2014001065A MX 2014001065 A MX2014001065 A MX 2014001065A MX 2014001065 A MX2014001065 A MX 2014001065A MX 2014001065 A MX2014001065 A MX 2014001065A
Authority
MX
Mexico
Prior art keywords
trimethoxyphenylamino
pyrimidinyl
formulations
new
hydrate
Prior art date
Application number
MX2014001065A
Other languages
English (en)
Other versions
MX339685B (es
Inventor
Farhan Abdul Karim Alhusban
Ian Paul Gabbott
Bindhumadhavan Gururajan
Dawn Sievwright
David Bradley Brook Simpson
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014001065(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of MX2014001065A publication Critical patent/MX2014001065A/es
Publication of MX339685B publication Critical patent/MX339685B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas que comprenden mas de un 15% p/p del compuesto de Fórmula (I), según se define en la presente, y/o un hidrato de este y una cantidad de uno o mas agentes efervescentes que sea suficiente para proporcionar una disolución satisfactoria in vitro; y que comprenden además uno o más ingredientes farmacéuticamente aceptables; y procesos para obtenerlas.
MX2014001065A 2011-07-28 2012-07-26 Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas. MX339685B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512621P 2011-07-28 2011-07-28
PCT/GB2012/051791 WO2013014454A1 (en) 2011-07-28 2012-07-26 New (trimethoxyphenylamino)pyrimidinyl formulations

Publications (2)

Publication Number Publication Date
MX2014001065A true MX2014001065A (es) 2014-08-01
MX339685B MX339685B (es) 2016-06-06

Family

ID=46875902

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001065A MX339685B (es) 2011-07-28 2012-07-26 Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.

Country Status (27)

Country Link
US (2) US8771648B2 (es)
EP (1) EP2736487B2 (es)
JP (1) JP6019116B2 (es)
KR (2) KR102090440B1 (es)
CN (1) CN103826610B (es)
AR (1) AR087371A1 (es)
AU (1) AU2012288632B2 (es)
BR (1) BR112014001999B1 (es)
CA (1) CA2843138C (es)
CY (1) CY1122596T1 (es)
DK (1) DK2736487T4 (es)
EA (1) EA028432B1 (es)
ES (1) ES2710423T5 (es)
FI (1) FI2736487T4 (es)
HR (1) HRP20190186T4 (es)
HU (1) HUE042611T2 (es)
LT (1) LT2736487T (es)
MX (1) MX339685B (es)
PL (1) PL2736487T5 (es)
PT (1) PT2736487T (es)
RS (1) RS58433B2 (es)
SI (1) SI2736487T2 (es)
SM (1) SMT201900071T1 (es)
TR (1) TR201901792T4 (es)
TW (1) TW201311251A (es)
UY (1) UY34223A (es)
WO (1) WO2013014454A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078026B1 (en) * 2006-11-21 2012-01-04 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
DK2736487T4 (da) 2011-07-28 2024-11-04 Rigel Pharmaceuticals Inc Nye (trimethoxyphenylamino)pyrimidinyl-formuleringer
PL3283551T3 (pl) 2015-04-02 2021-04-06 Stora Enso Oyj Kompozycja aktywowanej ligniny, sposób jej wytwarzania oraz jej zastosowanie
WO2016172053A1 (en) 2015-04-24 2016-10-27 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
SE542795C2 (en) 2018-10-08 2020-07-07 Stora Enso Oyj Process for preparing a resin
CA3184460A1 (en) * 2020-07-07 2022-01-13 Celgene Corporation Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the sam
US20230292795A1 (en) * 2020-07-24 2023-09-21 Dsm Ip Assets B.V. New fast dissolvable tablets

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DE60221787T2 (de) † 2002-03-04 2008-06-05 Orbus Pharma Inc. Zusammensetzungen mit schneller Freisetzung enthaltend Cefuroxime Axetil
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US20050113398A1 (en) 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
US20060051406A1 (en) * 2004-07-23 2006-03-09 Manjeet Parmar Formulation of insoluble small molecule therapeutics in lipid-based carriers
AU2005289426A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP4773456B2 (ja) † 2004-11-23 2011-09-14 ドン ファ ファーマシューティカル カンパニー リミテッド 生体利用率を向上させた経口用製剤
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
JP2009518443A (ja) * 2005-12-06 2009-05-07 リゲル ファーマシューティカルズ インコーポレーティッド 脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤
WO2007120980A2 (en) * 2006-02-17 2007-10-25 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2008061201A1 (en) * 2006-11-15 2008-05-22 Rigel Pharmaceuticals, Inc. Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds
EP2078026B1 (en) * 2006-11-21 2012-01-04 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
HUE039193T2 (hu) * 2007-11-07 2018-12-28 Rigel Pharmaceuticals Inc Nedves granulálás egy vízlágyító szerrel
HRP20170050T1 (hr) 2008-02-22 2017-03-10 Rigel Pharmaceuticals, Inc. Uporaba 2,4-pirimidindiamina za liječenje ateroskleroze
UA108077C2 (xx) * 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
US20110015155A1 (en) 2009-07-17 2011-01-20 Rigel Pharmaceuticals, Inc. Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses
CA2780777C (en) 2009-11-20 2017-12-05 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
EP2558474B1 (en) 2010-04-13 2015-11-25 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
DK2736487T4 (da) 2011-07-28 2024-11-04 Rigel Pharmaceuticals Inc Nye (trimethoxyphenylamino)pyrimidinyl-formuleringer

Also Published As

Publication number Publication date
PL2736487T3 (pl) 2019-06-28
EP2736487A1 (en) 2014-06-04
DK2736487T4 (da) 2024-11-04
FI2736487T4 (fi) 2024-10-31
EP2736487B1 (en) 2018-11-07
EA028432B1 (ru) 2017-11-30
US8771648B2 (en) 2014-07-08
ES2710423T3 (es) 2019-04-25
LT2736487T (lt) 2019-02-25
HUE042611T2 (hu) 2019-07-29
CY1122596T1 (el) 2021-01-27
BR112014001999A2 (pt) 2017-02-21
KR102090440B1 (ko) 2020-03-17
WO2013014454A1 (en) 2013-01-31
BR112014001999B1 (pt) 2023-11-28
AR087371A1 (es) 2014-03-19
EP2736487B2 (en) 2024-08-28
KR20190109576A (ko) 2019-09-25
SI2736487T2 (sl) 2025-06-30
CN103826610A (zh) 2014-05-28
DK2736487T3 (en) 2019-03-04
AU2012288632A1 (en) 2014-02-20
CN103826610B (zh) 2017-08-04
US8951504B2 (en) 2015-02-10
JP6019116B2 (ja) 2016-11-02
UY34223A (es) 2013-02-28
AU2012288632B2 (en) 2017-08-17
JP2014521630A (ja) 2014-08-28
TW201311251A (zh) 2013-03-16
MX339685B (es) 2016-06-06
SMT201900071T1 (it) 2019-02-28
KR20140058576A (ko) 2014-05-14
RS58433B2 (sr) 2025-01-31
US20130058876A1 (en) 2013-03-07
KR102024120B1 (ko) 2019-09-23
HRP20190186T1 (hr) 2019-03-22
CA2843138A1 (en) 2013-01-31
US20140271493A1 (en) 2014-09-18
HRP20190186T4 (hr) 2024-12-20
CA2843138C (en) 2020-06-02
RS58433B1 (sr) 2019-04-30
PL2736487T5 (pl) 2025-01-27
HK1198741A1 (en) 2015-06-05
SI2736487T1 (sl) 2019-04-30
PT2736487T (pt) 2019-02-13
EA201490363A1 (ru) 2014-06-30
ES2710423T5 (en) 2025-02-13
TR201901792T4 (tr) 2019-03-21

Similar Documents

Publication Publication Date Title
MX2014001065A (es) Formulaciones de (trimetoxifenilamino) pirimidilino nuevas.
MX361618B (es) Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.
MX337408B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
MX348823B (es) Formulaciones estables de linaclotida.
NZ708593A (en) Novel pyrazole derivative
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
MX2010014234A (es) Compuestos pirazol 436.
CA2818187C (en) Bromodomain inhibitors and uses thereof
IN2014MN01754A (es)
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MA34055B1 (fr) Chlorhydrate d'agomelatine hydrate et sa preparation
NZ630471A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
IN2014DN01619A (es)
GEP20135997B (en) Tricyclic indazole compound, method of their preparation and pharmaceutical composition containing thereof
TW200833335A (en) New pyridine analogues
MX2012013607A (es) Polisacarido de las semillas de tamarindo para usarse en el tatamiento de enfermedades inflamatorias.
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
IN2014MN02156A (es)
TW200833333A (en) New pyridine analogues
EA032913B1 (ru) Препараты производных пиримидиндиона
MX2013012038A (es) Combinacion de carotenoide, fitoestrogeno y vitamina c para la humectacion de la piel.
PH12015501389A1 (en) Pharmaceutical formulation of n- [5-[2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide
IN2014MN02433A (es)

Legal Events

Date Code Title Description
FG Grant or registration